SubsidieMeestersMagnetic Resonance at the Scale of a Cell
The HyperCell project aims to revolutionize cell research by developing a non-invasive benchtop tool for single-cell metabolic analysis, enhancing understanding of diseases and treatment responses.
Projectdetails
Introduction
The HyperCell project merges two groundbreaking technologies to validate a benchtop tool for cell metabolic analysis, promising to revolutionize cell research. It empowers researchers to explore individual cell metabolic profiles, unveiling hidden disease mechanisms, understanding organism development, and revealing treatment responses. This innovation fills a crucial gap in the field, as current methods struggle to provide reliable metabolic data at the micro to picolitre scale.
Non-Invasive Approach
HyperCell's standout feature is its non-invasive approach to deliver quantitative metabolic information at the single-cell level without disrupting cell metabolism. This unique capability positions ANNAIDA and NVISION as global leaders in NMR technology, offering an unmatched solution in the market.
Initial Application
The initial application for this technology is embryo analysis, addressing infertility, a widespread issue affecting one in six couples globally.
Project Focus
The project will focus on the following key areas:
- Optimization of NVISION's Quantum-Based Platform.
- Integration of the platform with ANNAIDA’s Embryospin Sensor Technology.
- Validation of the enhanced NMR spectrometers' sensitivity to metabolites via hyperpolarization, enabling real-time monitoring of intracellular metabolic activity.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.998.750 |
| Totale projectbegroting | € 1.998.750 |
Tijdlijn
| Startdatum | 1-4-2024 |
| Einddatum | 30-9-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- NVISION IMAGING TECHNOLOGIES GMBHpenvoerder
- ANNAIDA TECHNOLOGIES SA
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Optical Sequencing inside Live Cells with Biointegrated NanolasersHYPERION aims to revolutionize intracellular biosensing by using plasmonic nanolasers for real-time detection of RNA, enhancing our understanding of molecular processes in living cells. | ERC STG | € 1.577.695 | 2022 | Details |
Valorising magnetometry in cellsThis project aims to commercialize diamond magnetometry for measuring free radical generation in living cells, potentially leading to a startup focused on innovative diagnostic solutions. | ERC POC | € 150.000 | 2022 | Details |
Single Molecule Nuclear Magnetic Resonance Microscopy for Complex Spin SystemsThis project aims to enhance NMR sensitivity to single molecules using scanning probe microscopy, enabling groundbreaking insights in nanotechnology and impacting NMR and SPM markets. | EIC Pathfinder | € 2.994.409 | 2023 | Details |
Multidimensional in vivo metabolic flux analyses: Resolving immune cells based on in vivo metabolic phenotypesThe project aims to develop a novel nutrient uptake assay for analyzing immune cell metabolism in vivo, enhancing immunotherapy design for solid tumors through detailed metabolic insights. | ERC POC | € 150.000 | 2023 | Details |
Optical Sequencing inside Live Cells with Biointegrated Nanolasers
HYPERION aims to revolutionize intracellular biosensing by using plasmonic nanolasers for real-time detection of RNA, enhancing our understanding of molecular processes in living cells.
Valorising magnetometry in cells
This project aims to commercialize diamond magnetometry for measuring free radical generation in living cells, potentially leading to a startup focused on innovative diagnostic solutions.
Single Molecule Nuclear Magnetic Resonance Microscopy for Complex Spin Systems
This project aims to enhance NMR sensitivity to single molecules using scanning probe microscopy, enabling groundbreaking insights in nanotechnology and impacting NMR and SPM markets.
Multidimensional in vivo metabolic flux analyses: Resolving immune cells based on in vivo metabolic phenotypes
The project aims to develop a novel nutrient uptake assay for analyzing immune cell metabolism in vivo, enhancing immunotherapy design for solid tumors through detailed metabolic insights.